385 related articles for article (PubMed ID: 29153631)
21. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
[TBL] [Abstract][Full Text] [Related]
22. No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial.
Seifritz E; Möller HJ; Volz HP; Müller WE; Hopyan T; Wacker A; Schläfke S; Kasper S
Int J Neuropsychopharmacol; 2021 Mar; 24(3):171-180. PubMed ID: 33300578
[TBL] [Abstract][Full Text] [Related]
23. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo.
Hindmarch I; Dawson J; Stanley N
Sleep; 2005 Feb; 28(2):187-93. PubMed ID: 16171242
[TBL] [Abstract][Full Text] [Related]
24. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers.
Bernard K; Penelaud PF; Mocaër E; Donazzolo Y
J Clin Psychopharmacol; 2011 Aug; 31(4):441-8. PubMed ID: 21694627
[TBL] [Abstract][Full Text] [Related]
25. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users.
Koblan KS; Hopkins SC; Sarma K; Gallina N; Jin F; Levy-Cooperman N; Schoedel KA; Loebel A
Drug Alcohol Depend; 2016 Feb; 159():26-34. PubMed ID: 26794682
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis.
Brandt C; Borghs S; Elmoufti S; Mueller K; Townsend R; de la Loge C
Epilepsy Behav; 2017 Apr; 69():80-85. PubMed ID: 28236727
[TBL] [Abstract][Full Text] [Related]
27. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
[TBL] [Abstract][Full Text] [Related]
28. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
29. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans.
Busto U; Kaplan HL; Zawertailo L; Sellers EM
Clin Pharmacol Ther; 1994 Apr; 55(4):451-63. PubMed ID: 8162672
[TBL] [Abstract][Full Text] [Related]
31. Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men.
Ciraulo DA; Barnhill JG; Greenblatt DJ; Shader RI; Ciraulo AM; Tarmey MF; Molloy MA; Foti ME
J Clin Psychiatry; 1988 Sep; 49(9):333-7. PubMed ID: 3417618
[TBL] [Abstract][Full Text] [Related]
32. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
33. Assessment of abuse liability of Tramadol among experienced drug users: Double-blind crossover randomized controlled trial.
Das M; Jain R; Dhawan A; Kaur A
J Opioid Manag; 2016; 12(6):421-430. PubMed ID: 28059434
[TBL] [Abstract][Full Text] [Related]
34. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
Rolan P; Sargentini-Maier ML; Pigeolet E; Stockis A
Br J Clin Pharmacol; 2008 Jul; 66(1):71-5. PubMed ID: 18341673
[TBL] [Abstract][Full Text] [Related]
36. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
[TBL] [Abstract][Full Text] [Related]
37. [Brivaracetam for add-on treatment in focal epilepsy].
Strzelczyk A; Steinig I; Klein KM; Willems LM; Knake S; Rosenow F; Bauer S
Nervenarzt; 2016 Oct; 87(10):1086-1093. PubMed ID: 27389600
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid.
Feltner DE; Haig G
J Psychopharmacol; 2011 Jun; 25(6):763-73. PubMed ID: 20147572
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
Setnik B; McDonnell M; Mills C; Scart-Grès C; Robert P; Dayno JM; Schwartz JC
Sleep; 2020 Apr; 43(4):. PubMed ID: 31626696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
